0KFH Stock Overview
Provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for 0KFH from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Revenio Group Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €25.02 |
| 52 Week High | €35.74 |
| 52 Week Low | €23.38 |
| Beta | 1.44 |
| 1 Month Change | -6.02% |
| 3 Month Change | -5.02% |
| 1 Year Change | -1.84% |
| 3 Year Change | -44.87% |
| 5 Year Change | 27.05% |
| Change since IPO | 276.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0KFH | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -3.8% | -4.8% | -0.5% |
| 1Y | -1.8% | -4.5% | 8.5% |
Return vs Industry: 0KFH exceeded the UK Medical Equipment industry which returned -4.5% over the past year.
Return vs Market: 0KFH underperformed the UK Market which returned 8.4% over the past year.
Price Volatility
| 0KFH volatility | |
|---|---|
| 0KFH Average Weekly Movement | 5.8% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0KFH has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0KFH's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 241 | Jouni Toijala | www.reveniogroup.fi |
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; and iCare TONOVET an IOP measuring on animal patients by general veterinary practitioners, veterinary ophthalmologists, and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; and DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images.
Revenio Group Oyj Fundamentals Summary
| 0KFH fundamental statistics | |
|---|---|
| Market cap | €679.28m |
| Earnings (TTM) | €18.50m |
| Revenue (TTM) | €103.80m |
36.7x
P/E Ratio6.5x
P/S RatioIs 0KFH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0KFH income statement (TTM) | |
|---|---|
| Revenue | €103.80m |
| Cost of Revenue | €30.60m |
| Gross Profit | €73.20m |
| Other Expenses | €54.70m |
| Earnings | €18.50m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 29, 2025
| Earnings per share (EPS) | 0.70 |
| Gross Margin | 70.52% |
| Net Profit Margin | 17.82% |
| Debt/Equity Ratio | 10.3% |
How did 0KFH perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield58%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/16 04:53 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Revenio Group Oyj is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pia Rosqvist-Heinsalmi | Carnegie Investment Bank AB |
| Daniel Lepistö | Danske Bank |
| null null | Evli Bank plc |